罗莫索单抗成功调控一例接受血液透析的常染色体显性多囊肾病患者进行性骨质疏松
本文报告一例42岁接受血液透析的常染色体显性多囊肾病患者发生严重骨质疏松,表现为高钙血症、骨代谢指标异常及病理性骨折,骨活检示骨代谢紊乱及高骨转换。每月一次给予罗莫索单抗治疗10个月后,骨代谢指标改善,骨密度下降减缓。作者认为罗莫索单抗可能成为血液透析患者骨质疏松的治疗选择。
要点
- 病例为42岁男性血液透析患者,合并常染色体显性多囊肾病及严重骨质疏松。
- 每月一次罗莫索单抗治疗10个月后骨代谢指标改善,骨密度下降减缓。
- 作者认为罗莫索单抗可能是血液透析患者骨质疏松的治疗选择。
核心结论
- 作者认为罗莫索单抗可能成为接受血液透析患者骨质疏松的治疗选择,尤其是存在骨矿化障碍者。
研究设计与样本
- 个案报告:一例42岁接受血液透析的常染色体显性多囊肾病患者,每月一次给予罗莫索单抗治疗10个月。
主要发现
- 治疗前血清钙水平极高、骨代谢指标异常,并存在病理性骨折,骨活检示骨代谢紊乱及高骨转换。
- 每月一次罗莫索单抗治疗10个月后骨代谢指标改善,骨密度下降减缓。
关键数值与推荐
- 罗莫索单抗每月一次给药,共使用10个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoporosis is a crucial complication in patients with chronic kidney disease (CKD), similar to that in the general population. Although romosozumab, a monoclonal antibody targeting sclerostin, has been administered for patients with CKD, its clinical effectiveness in these patients, especially in patients on hemodialysis (HD), remains to be studied. Herein, we report the case of a 42-year-old man on HD who developed severe osteoporosis. Serum calcium levels were extremely high, bone metabolic markers were abnormal, and the patient had pathological fractures. The bone biopsy indicated a bone metabolism disorder and high bone turnover. We administered romosozumab once a month as an intervention for bone alteration. Through the 10-month usage, bone metabolic markers improved, and the decrease in bone mineral density was ameliorated. We hypothesized that romosozumab could be a therapeutic option for osteoporosis in patients undergoing HD, especially in those with bone mineralization disorders.
引用
- Suzuki T, Mizobuchi M, Yoshida S, et al. Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis. Osteoporos Int. 2022. PMID: 35980440. doi:10.1007/s00198-022-06534-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。